Article Sidebar
Views PDF: 101
DETERMINATION OF CYFRA21-1 AND CEA CONCENTRATION IN PATIENT’S BLOOD DIAGNOSED WITH SMALL CANCER LUNG CANCER
Main Article Content
Abstract
Objectives: 1) To determine the concentration of Cyfra 21-1 and CEA in patients’s blood non-small cell lung cancer and 2) Describe the relation between the concentration of Cyfra 21-1 and CEA with clinical, histological and imaging characteristics in patients diagnosed with non-small cell lung cancer. Study subjects: 94 patients were diagnosed with non-small cell lung cancer at 108 Central Military Hospital from January 2019 to June 2022. Methods: Cross-sectional descriptive. Cyfra 21-1 and CEA concentrations were quantified by MEIA method on Abbott i2000sr system. Results: Cyfra 21-1 and CEA concentrations ranged from 1.21-43 ng/mL and 1-111.39 ng/mL, respectively. The median values of Cyfra 21-1 and CEA were 4 ng/mL and 9 ng/mL, respectively. Cyfra 21-1 an CEA concentration increased in patients with NSCLC accounting for 48.9% and 66%, respectively. Conclusion: In patients with non-small cell lung cancer, there was a simultaneous increase in both CEA and Cyfra 21-1 markers. This is very useful in combining both markers to increase the sensitivity and specificity when used for diagnosis, treatment monitoring and prognosis of NSCLC
Article Details
Keywords
Non-small cell lung cancer, Cyfra21-1, CEA, Patient
References
2. Barlési F, Gimenez C, Torre J-P, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respiratory medicine. 2004;98(4): 357-62.
3. Trang VH, Hiếu NV, Hằng NTT, Anh NQ. KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI BIỂU MÔ TUYẾN DI CĂN NÃO CÓ ĐỘT BIẾN EGFR BẰNG TKIs THẾ HỆ 1. Tạp chí Y học Việt Nam. 2021;508(2).
4. Travis WD. Pathology of lung cancer. Clinics in chest medicine. 2002;23(1):65-81.
5. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran Jr WJ, Wu Y-L, et al. Lung cancer: current therapies and new targeted treatments. The Lancet. 2017;389(10066):299-311.
6. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Translational lung cancer research. 2016; 5(3):288.
7. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, editors. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo clinic proceedings; 2008: Elsevier.
8. Stieber P, Hasholzner U, Bodenmüller H, Nagel D, Sunder‐Plassmann L, Dienemann H, et al. CYFRA 21‐1: a new marker in lung cancer. Cancer. 1993;72(3):707-13.